Literature DB >> 23964893

Design and in vitro characterization of small unilamellar niosomes as ophthalmic carrier of dorzolamide hydrochloride.

Azza A Hasan1.   

Abstract

The objective of this work was to formulate and characterize non-ionic surfactant vesicles (niosomes) as an ocular carrier of dorzolamide hydrochloride (Dorzo); one of the antiglaucoma drugs. Niosomes were prepared of Cholesterol (Chol) with sorbitan monoesters (Span 20, 40, 60) or sorbitan trioleate (Span 85) in a molar ratio of 40:150. Those prepared from Span 40 were selected for further investigation on the effect of addition of dicetylphosphate (DCP) and polyoxyethylene fatty acid esters (either Tween 20, 40 or 80). All The batches were prepared using mechanical shaking technique, followed by sonication and then characterized using Zetasizer, transmission electron microscopy (TEM), calculating percent drug entrapment efficiency and cumulative percent released. Z-average sizes of the niosomes were between 25.9 and 165.5 nm. All niosomal formulations showed negative zeta potential charge. Dorzo was successfully entrapped in all of the formulations with entrapment efficiencies ranging between 34.81% and 97.66%. With reference to release profiles, Dorzo-loaded niosomal formulations showed significant reduction in cumulative percent drug released than Dorzo solution. High entrapment efficiencies, biphasic prolonged release rate and small particles size highlight Dorzo-loaded niosomal preparations as a promising ophthalmic carrier to prolong the drug lowering effect on the intraocular pressure.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23964893     DOI: 10.3109/10837450.2013.829095

Source DB:  PubMed          Journal:  Pharm Dev Technol        ISSN: 1083-7450            Impact factor:   3.133


  5 in total

1.  Physicochemical and Stability Evaluation of Topical Niosomal Encapsulating Fosinopril/γ-Cyclodextrin Complex for Ocular Delivery.

Authors:  Hay Marn Hnin; Einar Stefánsson; Thorsteinn Loftsson; Rathapon Asasutjarit; Dusadee Charnvanich; Phatsawee Jansook
Journal:  Pharmaceutics       Date:  2022-05-27       Impact factor: 6.525

2.  Enhancement of pharmacokinetic and pharmacological behavior of ocular dorzolamide after factorial optimization of self-assembled nanostructures.

Authors:  Enas A M R Afify; Ibrahim Elsayed; Mary K Gad; Magdy I Mohamed; Abd El-Moneim M R Afify
Journal:  PLoS One       Date:  2018-02-05       Impact factor: 3.240

3.  Development of Nanoemulsions for Wound Dressings Containing Cassia alata L. Leaf Extraction.

Authors:  Surat Sangkaew; Smith Wanmasae; Kingkan Bunluepeuch; Tassanee Ongtanasup; Siriwan Srisang; Chawan Manaspon; Philaslak Pooprommin; Komgrit Eawsakul
Journal:  Evid Based Complement Alternat Med       Date:  2022-10-11       Impact factor: 2.650

4.  Ocular Dorzolamide Nanoliposomes for Prolonged IOP Reduction: in-vitroand in-vivo Evaluation in Rabbits.

Authors:  Maryam Kouchak; Reza Bahmandar; Neda Bavarsad; Fereydoun Farrahi
Journal:  Iran J Pharm Res       Date:  2016       Impact factor: 1.696

5.  Sustained ocular delivery of Dorzolamide-HCl via proniosomal gel formulation: in-vitro characterization, statistical optimization, and in-vivo pharmacodynamic evaluation in rabbits.

Authors:  Nagwa Hussein Fouda; Randa Tag Abdelrehim; Doaa Abdelmagid Hegazy; Basant Ahmed Habib
Journal:  Drug Deliv       Date:  2018-11       Impact factor: 6.419

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.